Innovation in Psychopharmacology is Dead. Long Live Innovation in Psychopharmacology!  
What’s going on in our field? 

• Priorities of Big Pharma shifting away from CNS and especially from psychiatry
• Failed clinical trials littering the landscape
• Even known drugs don’t work in psychiatric trials
• Broken clinical trial apparatus
• Iterative step-wise improvements or ‘me-too’ agents not reimbursed
• Aggressive cost controls
• No new validated targets

Learning objectives - 

• Discuss the reasons for the slow down of innovative new treatments entering psychopharmacology and the exit of Big Pharma largely from psychiatry
• Show that future advances may be based on targeting symptoms that cut across a large array of psychiatric disorders
• Propose that effective new treatments will be based upon subpopulations defined mostly in the short run by symptoms but in the long run by genetic and imaging biomarkers